• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过过渡金属配位实现抗真菌唑类药物的复兴与重新利用以用于药物发现

Resurgence and Repurposing of Antifungal Azoles by Transition Metal Coordination for Drug Discovery.

作者信息

Cortat Youri, Zobi Fabio

机构信息

Department of Chemistry, University of Fribourg, Chemin du Musée 9, 1700 Fribourg, Switzerland.

出版信息

Pharmaceutics. 2023 Sep 28;15(10):2398. doi: 10.3390/pharmaceutics15102398.

DOI:10.3390/pharmaceutics15102398
PMID:37896159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10609764/
Abstract

Coordination compounds featuring one or more antifungal azole (AA) ligands constitute an interesting family of candidate molecules, given their medicinal polyvalence and the viability of drug complexation as a strategy to improve and repurpose available medications. This review reports the work performed in the field of coordination derivatives of AAs synthesized for medical purposes by discussing the corresponding publications and emphasizing the most promising compounds discovered so far. The resulting overview highlights the efficiency of AAs and their metallic species, as well as the potential still lying in this research area.

摘要

含有一种或多种抗真菌唑(AA)配体的配位化合物构成了一类有趣的候选分子家族,这是由于它们具有药物多价性以及药物络合作为改善和重新利用现有药物的策略的可行性。本综述通过讨论相应的出版物并强调迄今为止发现的最有前景的化合物,报告了在为医学目的合成的AA配位衍生物领域所开展的工作。所得概述突出了AA及其金属物种的有效性,以及该研究领域仍存在的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/bf8347558d06/pharmaceutics-15-02398-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/f846e3a0cb8e/pharmaceutics-15-02398-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/f32059f5b774/pharmaceutics-15-02398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9455cc9053a4/pharmaceutics-15-02398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/59d4d8348ca8/pharmaceutics-15-02398-sch002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/ae56eae53244/pharmaceutics-15-02398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9151116abb47/pharmaceutics-15-02398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/e3cf0e481e90/pharmaceutics-15-02398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/700733647d19/pharmaceutics-15-02398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/2804e9751039/pharmaceutics-15-02398-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/e3885961390e/pharmaceutics-15-02398-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/c6e8b4f3d6db/pharmaceutics-15-02398-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/d991c9c76dd8/pharmaceutics-15-02398-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/d1d90c6c99b2/pharmaceutics-15-02398-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/dc02fbfac624/pharmaceutics-15-02398-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/79db35e42016/pharmaceutics-15-02398-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/432eec85a348/pharmaceutics-15-02398-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9354cde82026/pharmaceutics-15-02398-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/bf8347558d06/pharmaceutics-15-02398-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/f846e3a0cb8e/pharmaceutics-15-02398-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/f32059f5b774/pharmaceutics-15-02398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9455cc9053a4/pharmaceutics-15-02398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/59d4d8348ca8/pharmaceutics-15-02398-sch002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/ae56eae53244/pharmaceutics-15-02398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9151116abb47/pharmaceutics-15-02398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/e3cf0e481e90/pharmaceutics-15-02398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/700733647d19/pharmaceutics-15-02398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/2804e9751039/pharmaceutics-15-02398-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/e3885961390e/pharmaceutics-15-02398-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/c6e8b4f3d6db/pharmaceutics-15-02398-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/d991c9c76dd8/pharmaceutics-15-02398-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/d1d90c6c99b2/pharmaceutics-15-02398-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/dc02fbfac624/pharmaceutics-15-02398-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/79db35e42016/pharmaceutics-15-02398-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/432eec85a348/pharmaceutics-15-02398-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/9354cde82026/pharmaceutics-15-02398-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6b/10609764/bf8347558d06/pharmaceutics-15-02398-g014.jpg

相似文献

1
Resurgence and Repurposing of Antifungal Azoles by Transition Metal Coordination for Drug Discovery.通过过渡金属配位实现抗真菌唑类药物的复兴与重新利用以用于药物发现
Pharmaceutics. 2023 Sep 28;15(10):2398. doi: 10.3390/pharmaceutics15102398.
2
The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax.经典的唑类抗真菌药物在体外具有很强的内分泌干扰作用,其抑制类固醇生成 CYP 酶的浓度低于治疗 Cmax。
Toxicology. 2019 Sep 1;425:152247. doi: 10.1016/j.tox.2019.152247. Epub 2019 Jul 19.
3
Antifungal promising agents of zinc(II) and copper(II) derivatives based on azole drug.基于唑类药物的锌(II)和铜(II)衍生物的有前途的抗真菌剂。
J Inorg Biochem. 2021 Jun;219:111401. doi: 10.1016/j.jinorgbio.2021.111401. Epub 2021 Feb 20.
4
Topical azole treatments for otomycosis.局部唑类药物治疗真菌性外耳道炎。
Cochrane Database Syst Rev. 2021 May 25;5(5):CD009289. doi: 10.1002/14651858.CD009289.pub2.
5
In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata.光滑念珠菌中线粒体DNA缺陷相关的对唑类药物的体外耐药性
J Med Microbiol. 1999 Jul;48(7):663-670. doi: 10.1099/00222615-48-7-663.
6
Effect of antifungal azoles on the heme detoxification system of malarial parasite.抗真菌唑类药物对疟原虫血红素解毒系统的影响。
J Biochem. 2002 Mar;131(3):437-44. doi: 10.1093/oxfordjournals.jbchem.a003119.
7
Azole antifungal agents.唑类抗真菌剂。
Clin Infect Dis. 1992 Mar;14 Suppl 1:S161-9. doi: 10.1093/clinids/14.supplement_1.s161.
8
Clinically used antifungal azoles as ligands for gold(III) complexes: the influence of the Au(III) ion on the antimicrobial activity of the complex.临床应用的抗真菌唑类化合物作为金(III)配合物的配体:金(III)离子对配合物抗菌活性的影响。
Dalton Trans. 2022 Mar 29;51(13):5322-5334. doi: 10.1039/d2dt00411a.
9
Activity of Metal-Azole Complexes Against Biofilms of and .金属-唑类配合物对 和 的生物膜活性。
Curr Pharm Des. 2020;26(14):1524-1531. doi: 10.2174/1381612826666200217120321.
10
Distribution, behavior and fate of azole antifungals during mechanical, biological, and chemical treatments in sewage treatment plants in China.在中国污水处理厂的机械、生物和化学处理过程中,唑类抗真菌药物的分布、行为和归宿。
Sci Total Environ. 2012 Jun 1;426:311-7. doi: 10.1016/j.scitotenv.2012.03.067. Epub 2012 Apr 18.

引用本文的文献

1
Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin.探索一座治疗金矿:金基抗风湿药物金诺芬的抗真菌潜力。
Int J Mol Sci. 2025 Aug 16;26(16):7909. doi: 10.3390/ijms26167909.
2
Boosting Antibiotic Efficacy of Azole Drugs against Methicillin-Resistant Staphylococcus Aureus by Coordination to Rhenium Carbonyl Complexes.通过与铼羰基配合物配位提高唑类药物对耐甲氧西林金黄色葡萄球菌的抗生素疗效。
Chembiochem. 2025 Jun 25:e2500368. doi: 10.1002/cbic.202500368.
3
Copper(II) and Zinc(II) Complexes with Bacterial Prodigiosin Are Targeting Site III of Bovine Serum Albumin and Acting as DNA Minor Groove Binders.

本文引用的文献

1
Silver(I) complexes containing N-heterocyclic carbene azole drugs: Synthesis, characterization, cytotoxic activity, and their BSA interactions.含氮杂环卡宾唑类药物的银(I)配合物:合成、表征、细胞毒性活性及其与牛血清白蛋白的相互作用
J Inorg Biochem. 2023 Sep;246:112303. doi: 10.1016/j.jinorgbio.2023.112303. Epub 2023 Jun 23.
2
Antibiotic Treatment in End Stage Cancer Patients; Advantages and Disadvantages.晚期癌症患者的抗生素治疗:利弊
Cancer Inform. 2023 Mar 29;22:11769351231161476. doi: 10.1177/11769351231161476. eCollection 2023.
3
Computer-Aided Drug Design and Synthesis of Rhenium Clotrimazole Antimicrobial Agents.
细菌血晶素铜(II)和锌(II)配合物靶向牛血清白蛋白 III 位点并充当 DNA 小沟结合物。
Int J Mol Sci. 2024 Aug 1;25(15):8395. doi: 10.3390/ijms25158395.
铼克霉唑抗菌剂的计算机辅助药物设计与合成
Antibiotics (Basel). 2023 Mar 20;12(3):619. doi: 10.3390/antibiotics12030619.
4
Multifunctional organometallic compounds for the treatment of Chagas disease: Re(I) tricarbonyl compounds with two different bioactive ligands.用于治疗恰加斯病的多功能有机金属化合物:具有两种不同生物活性配体的铼(I)三羰基化合物。
Dalton Trans. 2023 Feb 7;52(6):1623-1641. doi: 10.1039/d2dt03869b.
5
Repurposing antifungal drugs for cancer therapy.抗真菌药物再用于癌症治疗。
J Adv Res. 2023 Jun;48:259-273. doi: 10.1016/j.jare.2022.08.018. Epub 2022 Sep 5.
6
Synergetic Antimicrobial Activity and Mechanism of Clotrimazole-Linked CO-Releasing Molecules.克霉唑连接的一氧化碳释放分子的协同抗菌活性及作用机制
ACS Bio Med Chem Au. 2022 Aug 17;2(4):419-436. doi: 10.1021/acsbiomedchemau.2c00007. Epub 2022 Apr 8.
7
Copper Acts Synergistically With Fluconazole in by Compromising Drug Efflux, Sterol Metabolism, and Zinc Homeostasis.铜通过损害药物外排、甾醇代谢和锌稳态与氟康唑协同作用。
Front Microbiol. 2022 Jun 14;13:920574. doi: 10.3389/fmicb.2022.920574. eCollection 2022.
8
Theoretical Investigation by DFT and Molecular Docking of Synthesized Oxidovanadium(IV)-Based Imidazole Drug Complexes as Promising Anticancer Agents.理论研究通过 DFT 和分子对接合成的氧化钒(IV)-咪唑类药物配合物作为有前途的抗癌药物。
Molecules. 2022 Apr 27;27(9):2796. doi: 10.3390/molecules27092796.
9
Promising fluconazole based zinc(II) and copper(II) coordination polymers against Chagas disease.有前景的基于氟康唑的锌(II)和铜(II)配合物聚合物,可用于对抗恰加斯病。
J Inorg Biochem. 2022 Aug;233:111834. doi: 10.1016/j.jinorgbio.2022.111834. Epub 2022 Apr 21.
10
Metallodrugs: Mechanisms of Action, Molecular Targets and Biological Activity.金属药物:作用机制、分子靶标和生物学活性。
Int J Mol Sci. 2022 Mar 23;23(7):3504. doi: 10.3390/ijms23073504.